While the development and introduction of new pharmaceuticals have played a pivotal role in reducing US cancer deaths, winning the war on cancer is a multifaceted battle. Meanwhile, COVID-19 has affected virtually every aspect of cancer care, from the research and development of new therapies, to diagnosis and treatment.

Precision’s Joanna MacEwan and Jason Shafrin and Pfizer’s Farzad Ali explore the primary causes of reduced cancer mortality rates in the United States and how COVID-19 is impacting ongoing progress in the treatment of cancer.

Read the full article here!